Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration

dc.contributorHáskóli Íslandsen_US
dc.contributorUniversity of Icelanden_US
dc.contributor.authorDrobnjak, Tijana
dc.contributor.authorJónsdóttir, Anna Margrét
dc.contributor.authorHelgadottir, Helga
dc.contributor.authorRunólfsdóttir, Margrét Soffía
dc.contributor.authorMeiri, Hamutal
dc.contributor.authorSammar, Marei
dc.contributor.authorOsol, George J.
dc.contributor.authorMandalà, Maurizio
dc.contributor.authorHuppertz, Berthold
dc.contributor.authorGizurarson, Sveinbjorn
dc.contributor.departmentLyfjafræðideild (HÍ)en_US
dc.contributor.departmentFaculty of Pharmaceutical Sciences (UI)en_US
dc.contributor.schoolHeilbrigðisvísindasvið (HÍ)en_US
dc.contributor.schoolSchool of Health Sciences (UI)en_US
dc.date.accessioned2020-09-07T09:09:32Z
dc.date.available2020-09-07T09:09:32Z
dc.date.issued2019-03-27
dc.descriptionPublisher's version (útgefin grein)en_US
dc.description.abstractIntroduction: Reduced concentrations of placental protein 13 (PP13) during the first trimester of human pregnancy are associated with elevated risk for the subsequent development of preeclampsia, which is one of the deadliest obstetrical complications of pregnancy. Previous studies by our group have shown that PP13 lowers blood pressure in pregnant rats, increases the size and weight of pups and placentas, and induces vasodilation of resistance arteries through endothelial signaling pathways involving endothelial nitric oxid synthase and prostaglandin. Methods: In the present study, the effect of PP13 was investigated in nonpregnant female Sprague Dawley rats (n=27). Osmotic pumps were surgically implanted subcutaneously that released a constant dose of PP13 or saline over 7 days. Most animals were sacrificed 6 days after the end of PP13 release (on day 13), while some were sacrificed immediately at the end of day 7 (the last PP13 release day), to compare the short-and long-term impact of PP13 on vessels’ growth and size. Results: The uterine vessels were significantly expanded in the group exposed to recombinant PP13 (rPP13) compared to the control (saline) group. Both veins and arteries were significantly expanded by rPP13 with a more pronounced effect after 13 days compared to the corresponding vessels after 7 days. Furthermore, the long-term effect of treatment by rPP13 was more pronounced in the veins compared to the corresponding arteries. The effect of a PP13 variant with a histidine-tag (His-PP13) remained the same between 7 and 13 days. Conclusion: In conclusion, PP13 might play a key role in the expansive remodeling of the uterine vessels, reflecting what would happen if the rat was pregnant, preparing the uterine vasculature for the increase in uteroplacental blood flow, which is necessary for normal pregnancy. We suggest that PP13 could act by NO signaling pathways, a hypothesis that requires future study.en_US
dc.description.sponsorshipThe authors would like to thank Hy-Laboratories Ltd. for providing PP13 for this study through support provided by the European Union through ASPRE project (#601852). This study was mainly sponsored by Hananja ehf and Icelandic Research Fund (Rannís), grant no 163403-052. The funders had no influence on study design or the analysis of the data.en_US
dc.description.versionPeer Revieweden_US
dc.format.extent213-222en_US
dc.identifier.citationDrobnjak T, Jónsdóttir AM, Helgadóttir H, Runólfsdóttir MS, Meiri H, Sammar M, Osol G, Mandalà M, Huppertz B, Gizurarson S. Placental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration. Int J Womens Health. 2019;11:213-222 https://doi.org/10.2147/IJWH.S188303en_US
dc.identifier.doi10.2147/IJWH.S188303
dc.identifier.issn1179-1411
dc.identifier.journalInternational Journal of Women's Healthen_US
dc.identifier.urihttps://hdl.handle.net/20.500.11815/2042
dc.language.isoenen_US
dc.publisherInforma UK Limiteden_US
dc.relation.ispartofseriesInternational Journal of Women's Health;2019(11)
dc.relation.urlhttps://www.dovepress.com/placental-protein-13-pp13-stimulates-rat-uterine-vessels-after-slow-su-peer-reviewed-article-IJWHen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiomarkersen_US
dc.subjectENOSen_US
dc.subjectGalectinsen_US
dc.subjectHypertensionen_US
dc.subjectLGALS13en_US
dc.subjectPlacentaen_US
dc.subjectPreeclampsiaen_US
dc.subjectPregnancyen_US
dc.subjectRat vascular systemen_US
dc.subjectSlow releaseen_US
dc.subjectMeðgangaen_US
dc.subjectFylgjaen_US
dc.subjectHáþrýstinguren_US
dc.subjectKrampien_US
dc.subjectLyfjagerðen_US
dc.subjectLyfhrifafræðien_US
dc.titlePlacental protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administrationen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dcterms.licenseThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).en_US

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
ijwh-188303-placental-protein-13-pp13-stimulates-rat-uterine-vessels-a-032619.pdf
Stærð:
1.91 MB
Snið:
Adobe Portable Document Format
Description:
Publisher´s version

Undirflokkur